Income Statement Carl Zeiss Meditec AG
Equities
AFX
DE0005313704
Advanced Medical Equipment & Technology
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 27.52 EUR | +0.66% |
|
-1.71% | -31.20% |
| 02-02 | Zeiss announces NMPA approval in China for powerful ophthalmic microscopes enhancing surgical visualization | RE |
| 02-02 | CARL ZEISS MEDITEC AG : Barclays is less optimistic | ZD |
| Fiscal Period: September | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues | 1.65B | 1.9B | 2.09B | 2.07B | 2.23B | |||||
Total Revenues | 1.65B | 1.9B | 2.09B | 2.07B | 2.23B | |||||
Cost of Goods Sold, Total | 680M | 775M | 884M | 977M | 1.05B | |||||
Gross Profit | 967M | 1.13B | 1.21B | 1.09B | 1.18B | |||||
Selling General & Admin Expenses, Total | 365M | 437M | 503M | 558M | 627M | |||||
R&D Expenses | 232M | 291M | 349M | 343M | 326M | |||||
Other Operating Expenses | - | - | - | - | -917K | |||||
Other Operating Expenses, Total | 597M | 729M | 852M | 901M | 952M | |||||
Operating Income | 370M | 399M | 354M | 187M | 223M | |||||
Interest Expense, Total | -8.58M | -9.1M | -15.25M | -29.42M | -26.6M | |||||
Interest And Investment Income | 1.56M | 13.25M | 28.11M | 22.4M | 6.57M | |||||
Net Interest Expenses | -7.02M | 4.15M | 12.86M | -7.03M | -20.03M | |||||
Income (Loss) On Equity Invest. | - | - | -893K | -3.02M | 30K | |||||
Currency Exchange Gains (Loss) | -25.1M | -48.63M | 38.2M | 11.58M | -10.46M | |||||
Other Non Operating Income (Expenses) | 88K | -2.05M | -1.85M | 205K | -3.62M | |||||
EBT, Excl. Unusual Items | 338M | 352M | 402M | 189M | 189M | |||||
Merger & Related Restructuring Charges | - | -1.2M | -300K | -10.2M | - | |||||
Gain (Loss) On Sale Of Investments | 95K | 87K | - | - | - | |||||
Gain (Loss) On Sale Of Assets | 2.45M | - | - | - | - | |||||
Legal Settlements | - | - | - | 18.12M | - | |||||
Other Unusual Items | -1.84M | 52.25M | 10.88M | 43.8M | 4.68M | |||||
EBT, Incl. Unusual Items | 339M | 403M | 413M | 241M | 194M | |||||
Income Tax Expense | 102M | 108M | 121M | 60.71M | 51.55M | |||||
Earnings From Continuing Operations | 238M | 296M | 292M | 180M | 142M | |||||
Net Income to Company | 238M | 296M | 292M | 180M | 142M | |||||
Minority Interest | -1.24M | -2M | -1.61M | -1.43M | -1.14M | |||||
Net Income - (IS) | 236M | 294M | 290M | 179M | 141M | |||||
Net Income to Common Incl Extra Items | 236M | 294M | 290M | 179M | 141M | |||||
Net Income to Common Excl. Extra Items | 236M | 294M | 290M | 179M | 141M | |||||
Per Share Items | ||||||||||
Net EPS - Basic | 2.64 | 3.29 | 3.25 | 2.01 | 1.61 | |||||
Basic EPS - Continuing Operations | 2.64 | 3.29 | 3.25 | 2.01 | 1.61 | |||||
Basic Weighted Average Shares Outstanding | 89.44M | 89.44M | 89.44M | 88.85M | 87.54M | |||||
Net EPS - Diluted | 2.64 | 3.29 | 3.25 | 2.01 | 1.61 | |||||
Diluted EPS - Continuing Operations | 2.64 | 3.29 | 3.25 | 2.01 | 1.61 | |||||
Diluted Weighted Average Shares Outstanding | 89.44M | 89.44M | 89.44M | 88.85M | 87.54M | |||||
Normalized Basic EPS | 2.35 | 2.44 | 2.79 | 1.31 | 1.34 | |||||
Normalized Diluted EPS | 2.35 | 2.44 | 2.79 | 1.31 | 1.34 | |||||
Dividend Per Share | 0.9 | 1.1 | 1.1 | 0.6 | 0.55 | |||||
Payout Ratio | 18.93 | 27.39 | 33.88 | 54.95 | 37.19 | |||||
American Depositary Receipts Ratio (ADR) | 1 | 1 | 1 | 1 | 1 | |||||
Supplemental Items | ||||||||||
EBITDA | 389M | 419M | 375M | 225M | 274M | |||||
EBITA | 372M | 400M | 355M | 200M | 247M | |||||
EBIT | 370M | 399M | 354M | 187M | 223M | |||||
EBITDAR | 390M | 421M | 377M | 228M | 276M | |||||
Effective Tax Rate - (Ratio) | 29.95 | 26.66 | 29.22 | 25.21 | 26.59 | |||||
Current Domestic Taxes | 95.79M | 107M | - | - | - | |||||
Current Foreign Taxes | 5.51M | 7.64M | - | - | - | |||||
Total Current Taxes | 101M | 115M | 108M | 81.61M | 64.4M | |||||
Deferred Domestic Taxes | -1.9M | 791K | - | - | - | |||||
Deferred Foreign Taxes | 2.13M | -8.12M | - | - | - | |||||
Total Deferred Taxes | 223K | -7.33M | 12.4M | -20.89M | -12.85M | |||||
Normalized Net Income | 210M | 218M | 250M | 117M | 117M | |||||
Interest on Long-Term Debt | - | - | 2.54M | 4.11M | 4.09M | |||||
Non-Cash Pension Expense | 787K | 494K | -936K | -877K | 24K | |||||
Supplemental Operating Expense Items | ||||||||||
Selling and Marketing Expenses | 303M | 360M | 420M | 458M | 495M | |||||
General and Administrative Expenses | 60.75M | 76.68M | 83.48M | 101M | 131M | |||||
Research And Development Expense From Footnotes | 252M | 317M | 376M | 409M | 374M | |||||
Net Rental Expense, Total | 1.43M | 1.63M | 2.11M | 3.08M | 2.65M | |||||
Imputed Operating Lease Interest Expense | 1.04M | 954K | 1.81M | 2.04M | 1.04M | |||||
Imputed Operating Lease Depreciation | 397K | 678K | 294K | 1.04M | 1.61M |
- Stock Market
- Equities
- AFX Stock
- Financials Carl Zeiss Meditec AG
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















